SureNano Science Aims to Overcome GLP-1 Therapy Limitations with Triple Agonist Peptide
SureNano Science Ltd. is developing GEP-44, a triple agonist peptide targeting GLP-1 and PYY receptors, to address efficacy, tolerability, and delivery challenges in the rapidly expanding obesity and metabolic disease market.
The GLP-1 market is experiencing explosive growth, and microcap company SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) is positioning itself as a contender with its subsidiary GlucaPharm Inc. and its patented triple agonist peptide GEP-44. Licensed from Syracuse University, GEP-44 is designed to target GLP-1 and peptide YY receptors Y1 and Y2, potentially overcoming limitations of first-generation GLP-1 therapies, including efficacy, tolerability, and delivery flexibility, according to a BioMedWire editorial featuring the company.
SureNano is developing GEP-44 as a next-generation treatment for obesity and metabolic disorders, with a focus on improved tolerability and non-injectable delivery options. The company is evaluating oral, sublingual, and intranasal delivery approaches, which could significantly expand patient access and adherence. This strategy addresses a key pain point of current GLP-1 therapies, which are primarily injectable and associated with gastrointestinal side effects.
The editorial highlights SureNano alongside established and emerging metabolic disease companies such as Merck & Co. (NYSE: MRK), AbbVie (NYSE: ABBV), Viking Therapeutics (NASDAQ: VKTX), and Altimmune (NASDAQ: ALT), underscoring the accelerating momentum across the obesity, diabetes, and cardiometabolic treatment landscape. With the global GLP-1 market projected to grow substantially, SureNano’s entry as a microcap participant could offer a differentiated approach.
SureNano’s broader platform includes early-stage formulation and delivery technologies that could expand its long-term therapeutic scope. The company initially focused on the sale and distribution of the SureNano(TM) surfactant, a ready-to-mix food grade compound for nanoemulsions, but is now pivoting toward pharmaceutical development through GlucaPharm.
For more details on the editorial, visit https://ibn.fm/2NGrw. The latest news and updates regarding SURNF are available in the company’s newsroom at https://ibn.fm/SURNF.